Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Hoth Therapeutics
Sponsored
content by Hoth Therapeutics
JO
Jolt_Communications
Community Contributor
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
View narrative
US$5.30
FV
78.1% undervalued
intrinsic discount
0%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
New
narrative
PayPal Holdings
ZW
Zwfis
Community Contributor
PayPal's Future Growth Through Venmo and Merchant Solutions
PayPal at it's surface might not seem like fanciest option available; but as you take a deeper dive into the company it has a lot more to offer than just the app we use for transactions and sending money to others. Most of their revenue comes from transactions while they also source some revenue from other added value services like: Payment Gateway Subscriptions Interest and fees from consumer loans and merchant loans Other credit products referrals partnerships One other source that recently has begun to catch traction for them is Venmo; which is quite similar to the normal services of PayPal but has been very popular with younger populations.
View narrative
US$105.25
FV
33.3% undervalued
intrinsic discount
7.22%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
1
users have commented on this narrative
9
users have followed this narrative
New
narrative
IREN
BL
BlackGoat
Community Contributor
IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers
"Investing in a bitcoin miner?! How dare you!" endthefud.org Summary IREN owns and operates 4 Bitcoin mining sites in North America, powered by 100% renewable energy, leveraging 'stranded energy' from hydro and solar power plants.
View narrative
US$26.54
FV
0.2% undervalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
4
users have commented on this narrative
69
users have followed this narrative
27 days ago
author updated this narrative
Cadeler
MA
Mandelman
Community Contributor
Cadeler set to grow with market.
Catalysts Structural market tailwinds: Offshore wind installations are projected to grow from approximately 8 GW in 2024 to 34 GW by 2030 (28% CAGR), supported by strong policy initiatives in the EU, U.S., and China targeting over 400 GW of capacity. Source.
View narrative
NOK 95.36
FV
46.4% undervalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
GSK
DA
DailyInvestors
Community Contributor
GSK: March Madness Lineup
March Madness is here, or so they say on the basketball courts. But Marchs madness is slowly moving off to more than just the courts.
View narrative
UK£78.00
FV
81.5% undervalued
intrinsic discount
49.03%
Revenue growth p.a.
Set Fair Value
2
users have liked this narrative
1
users have commented on this narrative
16
users have followed this narrative
6 months ago
author updated this narrative
Lantronix
TH
thorinsteady
Community Contributor
Good Value for IOT and AI play
Key Takeaways Reached Cashflow profitability in 2023 Strong player in IOT driven by AI Founded 1989. Was around $60 during dot com bubble but has been stagnant since.
View narrative
US$5.60
FV
11.3% undervalued
intrinsic discount
20.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
6 months ago
author updated this narrative
Rheinmetall
NO
Noggerno
Community Contributor
Rheinmetall could get 20-25% of EU-NATO 3%-GDP defence spending
If European NATO members would raise their military spending to ~3% of their GDP, this would mean a combined yearly spending of over 500b€. Rheinmetall management assumed on 12th March 2025 that 20% to 25% of the entire military spending could be spent with Rheinmetall.
View narrative
€7.57k
FV
76.9% undervalued
intrinsic discount
64.00%
Revenue growth p.a.
Set Fair Value
34
users have liked this narrative
7
users have commented on this narrative
91
users have followed this narrative
6 months ago
author updated this narrative
Pfizer
FR
Francisco
Community Contributor
Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency
I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines.
View narrative
US$30.62
FV
19.1% undervalued
intrinsic discount
11.82%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
26
users have followed this narrative
6 months ago
author updated this narrative
Greenwich LifeSciences
WH
White_valkyrie
Community Contributor
Greenwich LifeSciences will eye a valued future at $460 a share, with GP2 leading the way.
*DISCLAIMER: *This article is NOT financial advice of any kind, i am NOT a financial adviser, this content should NOT be construed as an offer, recommendation or inducement to buy or sell Greenwich Lifesciences $GLSI stock. Do yor own Due diligence with this type of products before taking from granted any of these opinions.
View narrative
US$460.00
FV
97.5% undervalued
intrinsic discount
103.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
1
users have commented on this narrative
16
users have followed this narrative
6 months ago
author updated this narrative
DRC Systems India
DI
DineshManoharan
Community Contributor
Potential Multibagger
DRC Systems: Significant Upside Potential (Q3 FY25 - Dec 2024 Analysis) In its recent quarterly report , DRC Systems, a software product company, indicated that it expects to bag "several million dollars" in annual contracts for its newly developed software. Given the nature of the software business—where incremental costs are minimal—this revenue could have a substantial impact on the company's bottom line.
View narrative
₹37.00
FV
46.8% undervalued
intrinsic discount
27.32%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
6 months ago
author updated this narrative
Apple
DA
DailyInvestors
Community Contributor
Apple: Updates
On 3-11 Apple just unvieled a concert experience with their Apple Vision Pro, proving to millions that they are holding the best technology currently in the market. It may be over-priced but with the technology and security features, it is a Must Have.
View narrative
US$309.04
FV
24.9% undervalued
intrinsic discount
9.69%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
35
users have followed this narrative
6 months ago
author updated this narrative
Coherus Oncology
NE
neofeudal
Community Contributor
Coherus BioSciences will see 16% revenue growth driving future value
Coherus is a promising company that did a bad borrowing and has more than paid the price. Its convertible bondholders created a short hedge and have inflicted massive damage on the company's SP.
View narrative
US$15.42
FV
92.5% undervalued
intrinsic discount
16.00%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
6 months ago
author updated this narrative
PlayWay
DZ
Dzitkowskik
Community Contributor
Betting on PlayWay's Game Releases Could Push Stock to 400 PLN by 2027
Outlook for the Next Few Years (2025–2027) Bullish Case Catalysts : Successful 2025 game releases (e.g., from Madnetic Games or core franchises like Car Mechanic Simulator) could boost revenue and sentiment, potentially pushing the stock toward 350–400 PLN by 2026, as some users suggest. The gaming industry’s growth, especially in mobile and console markets, could amplify this if PlayWay capitalizes on it.
View narrative
zł293.45
FV
7.3% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
6 months ago
author updated this narrative
Value any company in seconds
Popular companies